Author: Ken Dropiewski

Ra Medical Systems Reports 2019 Fourth Quarter and Full Year Financial Results

CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three and 12 months ended December 31, 2019 and provides a business update. Recent Operational Highlights Enrolled the first patient in a […]

Correvio Partners with Hong Kong Teson Pharma Limited for the Commercialization of Aggrastat® in China

VANCOUVER and HONG KONG, March 10, 2020 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, and Hong Kong Teson Pharma Limited (Teson), a privately-held pharmaceutical company, today announced that Correvio International Sàrl, a wholly owned subsidiary of Correvio, and Teson have entered into an exclusive agreement […]

FDA Inks Research Collaboration Agreement with AnaBios Focused on Human Primary Cardiomyocytes

SAN DIEGO, March 10, 2020 /PRNewswire/ — Today, AnaBios announced a Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) to study adult human primary cardiomyocytes as a reference for cellular properties and drug-induced effects on cardiac function. Under the RCA, the FDA Center for Drug Evaluation and Research (CDER) […]

Carag First-ever Septal Occluder With Bioresorbable, Metal-free Framework Available to Patients Through New European Registry

First 3-year-old patient successfully implanted and discharged from hospital in Berlin BAAR, Switzerland and BERLIN, March 10, 2020 /PRNewswire/ — CARAG AG, a Swiss privately held medical device development company, announced today the successful implantation of the first-ever transcatheter septal occluder with bioresorbable, metal-free framework, as part of a new international post-market registry. The […]

Stereotaxis Reports 2019 Full Year Financial Results

ST. LOUIS, March 10, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2019. “The past year was transformative for Stereotaxis with significant progress financially, commercially and […]

Florida Cardiologist Zachariah P. Zachariah, M.D. Joins BioSig Technologies, Inc. Advisory Board

One of the nation’s leading cardiologists and Medical Director of UHealth Cardiology to advise on clinical practices Westport, CT, March 10, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity […]

Catalyst Marketing Agency Wins CryoLife Business

Biomedical Company Hires Denver Agency for Strategic Guidance and Marketing Support DENVER–(BUSINESS WIRE)–Catalyst, a Denver marketing agency, today announced that they were selected by CryoLife, a biomedical company, for marketing services. The marketing services include design, content development and sales enablement tools creation. Headquartered in suburban Atlanta, Georgia, CryoLife is one of the […]

NanoSurface Bio Executes Exclusive License of Heart-on-Chip Technology Launched Into Space

SEATTLE–(BUSINESS WIRE)–NanoSurface Biomedical announced today that it has executed an exclusive IP license agreement related to innovative heart-on-chip technology developed by researchers at the University of Washington (UW). An experimental system built from the same heart-on-chip technology was launched into space on Friday, March 6, 2020 at 11:50 PM EST aboard […]

Heartseed and ITOCHU CHEMICAL FRONTIER Sign Capital Alliance Agreement to Explore iPSC and Cardiomyocyte Business Opportunities

TOKYO–(BUSINESS WIRE)–Heartseed Inc. (hereinafter Heartseed), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for the treatment of heart failure (HF), today announced it has entered into agreement with ITOCHU CHEMICAL FRONTIER Corporation (headquartered in Minato-ku, Tokyo; President & CEO Tsutomu Miyazaki, hereinafter ICF) to form a financial business partnership. In accordance […]